CL
ITCI

CSS LLC’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

CSS LLC’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,904
Closed -$3.81M – 1205
2025
Q1 		$3.81M Buy
+28,904
New +$3.6M 0.21% 85
2023
Q1 		– Sell
-44,189
Closed -$2.34M – 933
2022
Q4 		$2.34M Sell
44,189
-1,066
-2% -$53.4K 0.13% 153
2022
Q3 		$2.11M Sell
45,255
-14,513
-24% -$758K 0.1% 218
2022
Q2 		$3.41M Sell
59,768
-773
-1% -$43.8K 0.14% 165
2022
Q1 		$3.71M Buy
60,541
+34,287
+131% +$1.78M 0.13% 147
2021
Q4 		$1.37M Buy
26,254
+4,682
+22% +$197K 0.05% 345
2021
Q3 		$804K Buy
21,572
+17,299
+405% +$601K 0.03% 482
2021
Q2 		$174K Sell
4,273
-26,515
-86% -$980K 0.01% 868
2021
Q1 		$1.04M Sell
30,788
-18,800
-38% -$652K 0.04% 374
2020
Q4 		$1.58M Sell
49,588
-15,398
-24% -$405K 0.06% 239
2020
Q3 		$1.67M Buy
64,986
+39,101
+151% +$892K 0.08% 208
2020
Q2 		$664K Buy
25,885
+2,303
+10% +$46.6K 0.04% 335
2020
Q1 		$362K Buy
23,582
+11,957
+103% +$260K 0.03% 349
2019
Q4 		$399K Buy
+11,625
New +$140K 0.02% 392

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

CSS LLC's ITCI Position: Q2 2025 in Review

CSS LLC sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 28,904 shares — an estimated $3.81M sold.

CSS LLC first reported a position in ITCI in Q4 2019 and held it in 14 quarters. The position peaked at $3.81M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • CSS LLC reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • CSS LLC sold 28,904 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $3.81M.
  • CSS LLC first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 14 quarters.
  • CSS LLC's Intra-Cellular Therapies Inc. position peaked at $3.81M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on CSS LLC's 13F filing for Q2 2025, filed 14 Aug 2025.